Comparative Evaluation of Lower Gadolinium Doses for MR Imaging of Meningiomas: How Low Can We Go?

References

1. 1.↵
   1. Yuh WT,
   2. Fisher DJ,
   3. Engelken JD, et al

   . MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 1991;180:485–91 doi:10.1148/radiology.180.2.2068317 pmid:2068317

   CrossRefPubMed
2. 2.↵
   1. Seidl Z,
   2. Vymazal J,
   3. Mechl M, et al

   . Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT study). AJNR Am J Neuroradiol 2012;33:1050–58 doi:10.3174/ajnr.A3033 pmid:22383237

   Abstract/FREE Full Text
3. 3.↵
   1. Layne KA,
   2. Dargan PI,
   3. Archer JRH, et al

   . Gadolinium deposition and the potential for toxicological sequelae – a literature review of issues surrounding gadolinium‐based contrast agents. Br J Clin Pharmacol 2018;84:2522–34 doi:10.1111/bcp.13718 pmid:30032482

   CrossRefPubMed
4. 4.↵
   1. Bennett CL,
   2. Qureshi ZP,
   3. Sartor O, et al

   . Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J 2012;5:82–88 doi:10.1093/ckj/sfr172 pmid:22833806

   CrossRefPubMed
5. 5.↵
   1. Kümmerer K,
   2. Helmers E

   . Hospital effluents as a source of gadolinium in the aquatic environment. Environ Sci Technol 2000;34:573–77 doi:10.1021/es990633h

   CrossRef
6. 6.↵
   1. Rogowska J,
   2. Olkowska E,
   3. Ratajczyk W, et al

   . Gadolinium as a new emerging contaminant of aquatic environments. Environ Toxicol Chem 2018;37:1523–34 doi:10.1002/etc.4116 pmid:29473658

   CrossRefPubMed
7. 7.↵
   1. He JQ,
   2. Michael C,
   3. Li G, et al

   . Noncontrast T2-weighted magnetic resonance imaging sequences for long-term monitoring of asymptomatic convexity meningiomas. World Neurosurg 2020;135:e100–05 doi:10.1016/j.wneu.2019.11.051 pmid:31734418

   CrossRefPubMed
8. 8.↵
   1. Rahatli FK,
   2. Donmez FY,
   3. Kesim C, et al

   . Can unenhanced brain magnetic resonance imaging be used in routine follow up of meningiomas to avoid gadolinium deposition in brain? Clin Imaging 2019;53:155–61 doi:10.1016/j.clinimag.2018.10.014 pmid:30343167

   CrossRefPubMed
9. 9.↵
   1. Voß KM,
   2. Spille DC,
   3. Sauerland C, et al

   . The Simpson grading in meningioma surgery: does the tumor location influence the prognostic value? J Neurooncol 2017;133:641–51 doi:10.1007/s11060-017-2481-1 pmid:28527009

   CrossRefPubMed
10. 10.↵
    1. Schneider G,
    2. Kirchin MA,
    3. Pirovano G, et al

    . Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging 2001;14:525–39 doi:10.1002/jmri.1216 pmid:11747004

    CrossRefPubMed
11. 11.↵
    1. Haustein J,
    2. Laniado M,
    3. Niendorf HP, et al

    . Administration of gadopentetate dimeglumine in MR imaging of intracranial tumors: dosage and field strength. AJNR Am J Neuroradiol 1992;13:1199–206 pmid:1636537

    Abstract/FREE Full Text
12. 12.↵
    1. DeLano MC,
    2. Spampinato MV,
    3. Chang EY, et al

    . Dose‐lowering in contrast‐enhanced MRI of the central nervous system: a retrospective, parallel‐group comparison using gadobenate dimeglumine. J Magn Reson Imaging 2021;54:1660–75 doi:10.1002/jmri.27731

    CrossRefPubMed
13. 13.↵
    1. Sathraju S,
    2. Johnson KY,
    3. Cicalese KV, et al

    . Reducing gadolinium exposure in patients undergoing monitoring for meningiomas. Cureus 2023;15:e37492 doi:10.7759/cureus.37492 pmid:37187666

    CrossRefPubMed
14. 14.↵
    1. Boto J,
    2. Guatta R,
    3. Fitsiori A, et al

    . Is contrast medium really needed for follow-up MRI of untreated intracranial meningiomas? AJNR Am J Neuroradiol 2021;42:1421–28 doi:10.3174/ajnr.A7170 pmid:34117017

    Abstract/FREE Full Text
15. 15.↵
    1. Raban D,
    2. Patel SH,
    3. Honce JM, et al

    . Intracranial meningioma surveillance using volumetrics from T2‐weighted MRI. J Neuroimaging 2021;32:134–40 doi:10.1111/jon.12926 pmid:34506680

    CrossRefPubMed
16. 16.↵
    1. Oya S,
    2. Kim S-H,
    3. Sade B, et al

    . The natural history of intracranial meningiomas. J Neurosurg 2011;114:1250–56 doi:10.3171/2010.12.JNS101623 pmid:21250802

    CrossRefPubMed
17. 17.↵
    1. Bruder O,
    2. Schneider S,
    3. Nothnagel D, et al

    . Acute adverse reactions to gadolinium-based contrast agents in CMR. JACC Cardiovasc Imaging 2011;4:1171–76 doi:10.1016/j.jcmg.2011.06.019

    Abstract/FREE Full Text
18. 18.↵
    1. Broome DR

    . Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiology 2008;66:230–34 doi:10.1016/j.ejrad.2008.02.011 pmid:18372138

    CrossRefPubMedWeb of Science